[Skip to Content]
[Skip to Content Landing]
Editorial
June 6, 2001

Selection of Antihypertensive Therapy for Patients With Hypertensive Renal Disease

Author Affiliations

Author Affiliation: Department of Cardiology, Veterans Affairs Medical Center, Washington, DC.

JAMA. 2001;285(21):2774-2776. doi:10.1001/jama.285.21.2774

Hypertension is a major contributor to cardiovascular morbidity and mortality in industrialized countries. During the last 3 decades, multiple prospective randomized trials, reported individually or in meta-analyses,1 demonstrated a dramatic reduction of vascular events attributable to hypertension. At the same time, however, the incidence of end-stage renal disease (ESRD) and congestive heart failure (CHF) has steadily increased.2,3 African Americans are particularly affected by these trends, since they have a higher prevalence and exhibit more severe forms of hypertension, resulting in higher rates of vascular complications. In particular, ESRD attributable to hypertension has increased at a rate that is several-fold higher among African American patients than white patients.4 Although tight blood pressure control is known to be a crucial factor in preventing progression of renal disease, other factors are undoubtedly involved. The potential renal protective effect of specific pharmacologic therapy has been addressed in only a few studies. Recently published reports indicate benefits from angiotensin-converting enzyme inhibitor (ACEI) therapy in patients with diabetes and in those with proteinuria without diabetes,5,6 but these studies included mostly white patients.

First Page Preview View Large
First page PDF preview
First page PDF preview
×